HCWB: HCW Biologics, Inc. Price to Sales
HCW Biologics Inc. (HCWB) develops cell therapies that mimic the benefits of fasting to combat oncology and aging. The company's smoothed P/S ratio reflects valuation dynamics, with the current value standing at 0.30. The TOBI platform enables the synthesis of unique anti-inflammatory proteins, providing a niche priority. However, the R&D stage limits scalability, as the expansion of research triggers a proportional increase in laboratory costs.
HCW Biologics Inc. (HCWB) - metric breakdowns and financial figures
- stock price and consensus target price:
- market capitalization information:
- shareholders' equity book value data:
- debt obligations and liquidity statistics:
Total Debt to Equity Ratio HCW Biologics Inc.|HCWB - Long-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital hcwbiologics.com|HCWB - Company Aggregate Debts|Debt to Book Capitalization Ratio HCW Biologics Inc|HCWB - Company Long-Term Debts|Short-Term Debt Volume HCW Biologics|Immediate Liquidity hcwbiologics.com
- earnings and valuation multiples information:
HCWB - Company Net Income|Expected Profit HCW Biologics Inc.|HCWB - Price to Earnings Ratio|Projected Price to Earnings Ratio hcwbiologics.com|HCWB - PEG Multiple|Enterprise Value to EBITDA Multiple HCW Biologics Inc|HCWB - Operating profit EBITDA|Net earnings per share for the last four quarters HCW Biologics|HCWB - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months hcwbiologics.com|HCWB - Earnings per share growth in current year|Consensus forecast of earnings per share growth for next year HCW Biologics Inc.
- issuer revenue and sales details:
General company analysis:HCW Biologics, Inc. HCWB
To assess the investment attractiveness of HCW Biologics Inc., it is critical to compare the business's market value with its actual revenues. This P/S multiple chart demonstrates the ratio of market capitalization to revenue, allowing for a determination of the overvaluation level of biotech sector assets and an assessment of how much the market is willing to pay for an innovative immunotherapy platform in anticipation of future capital growth.
Competing companies
argenx.com - Market Cap to Revenue Ratio|P/S Multiple BNTX (BioNTech)|Abivax Pharma (ABVX) - Price to Sales|ADMA Bio - P/S Multiple|Market Capitalization-to-Revenue Ratio PTGX (Protagonist Corp)|IMVT: P/S Multiple|Market Cap to Revenue kiniksa.com|Market Cap to Revenue GRFS|Market Cap to Revenue Adaptive Biotech (ADPT)|Market Cap to Revenue CLDX (Celldex)|AUPH (Aurinia Corp) - Market Capitalization-to-Revenue Ratio|P/S Multiple BCRX (BioCryst)|veratx.com - Price-to-Revenue Ratio|Dianthus Therapeutics, Inc. - P/S Multiple|Price-to-Revenue Coefficient Pharvaris NV PHVS|AbCellera Biologics Inc (ABCL) - Price-to-Revenue Ratio|Price to Sales Tourmaline (TRML)|Price-to-Revenue Ratio Precigen, Inc.|Price-to-Revenue Ratio PHAR|Price-to-Revenue Ratio Nektar Therapeutics Inc. (NKTR)|UPB - Price to Sales|P/S Multiple ZBIO (Zenas Biopharma, Inc.)|Price-to-Revenue Multiple Immunome Bio|Gossamer Bio, Inc. - P/S Multiple|Price-to-Revenue Coefficient kalvista.com KALV|SEPN: P/S Multiple|Market Cap to Revenue Pieris Pharma|Price-to-Revenue Ratio Savara Corp|Rigel Corp (RIGL) - Price-to-Revenue Coefficient|Market Cap to Revenue ANAB (AnaptysBio, Inc.)|ATXS (astriatx.com) - Market Capitalization-to-Revenue Ratio|P/S Multiple ENGN (enGene)|Price-to-Revenue Coefficient RAPT Therapeutics Inc. (RAPT)|JBIO - Price-to-Revenue Ratio|ACRS (Aclaris Therapeutics, Inc) - Market Cap to Revenue Ratio|KYTX: P/S Multiple|Market Cap to Revenue tizianalifesciences.com|Market Cap to Revenue CABA|Ventyx Biosciences Inc. (VTYX) - Price-to-Revenue Coefficient|P/S Multiple THTX|AVTX (Avalo Therapeutics Inc) - Market Capitalization-to-Revenue Ratio|P/S Multiple ELDN (Eledon Pharmaceuticals)|AGEN - Market Cap to Revenue|CLYM: Market Cap to Revenue|Zura Bio Ltd (ZURA) - Market Cap to Revenue|ATYR: P/S Multiple|ADAG (Adagene Inc.) - Price-to-Revenue Ratio|Price-to-Revenue Ratio ImageneBio|Shattuck Therapeutics - Price-to-Sales Ratio|P/S Multiple EQ|CNTB (connectbiopharm.com) - Market Capitalization-to-Revenue Ratio|P/S Multiple IMUX (Immunic)|P/S Multiple Atara Biotherapeutics, Inc. ATRA|IFRX - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio XFOR (x4pharma.com)|adicetbio.com (ACET) - Price-to-Revenue Ratio|Market Cap to Revenue Celularity|INMB (INmune Bio Corp) - P/S Multiple|P/S Multiple Barinthus Biotherapeutics Corp|Market Cap to Revenue KZR (Kezar Life Sciences)|SABS (sabbiotherapeutics.com) - Market Capitalization-to-Revenue Ratio|P/S Multiple AKTX (Akari Therapeutics Plc)|Price-to-Revenue Coefficient Enlivex Therapeutics Ltd (ENLV)|QTTB - Price-to-Revenue Ratio|GeoVax Corp (GOVX) - Market Cap to Revenue|Edesa Biotech, Inc. (EDSA) - Price-to-Revenue Ratio|Market Cap to Revenue ibioinc.com|Market Cap to Revenue CARM|P/S Multiple XTL Biopharmaceuticals Ltd|Price-to-Revenue Ratio Bolt Biotherapeutics (BOLT)|aptevotherapeutics.com - Market Cap to Revenue Ratio|P/S Multiple AIM (AIM ImmunoTech Inc.)|Aditxt Inc. (ADTX) - Price to Sales|GRI Bio - P/S Multiple|Market Capitalization-to-Revenue Ratio XRTX (XORTX Therapeutics Inc)|HIND: P/S Multiple|Market Cap to Revenue Revelation Biosciences Corp|Market Cap to Revenue INDP|Market Cap to Revenue scinai.com (SCNI)|Market Cap to Revenue CALI (CalciMedica, Inc.)|AFMD (affimed.com) - Market Capitalization-to-Revenue Ratio|P/S Multiple ALLK (Allakos)|HOOKIPA Pharma, Inc. - Price-to-Revenue Ratio|IGM Bio - P/S Multiple|Price-to-Revenue Coefficient iteostherapeutics.com ITOS|Ocean Biomedical (OCEA) - Price-to-Revenue Ratio|Price to Sales TC BioPharm (Holdings) Plc (TCBP)|Price-to-Revenue Ratio Third Harmonic Bio, Inc
